The scope of the existing EU-Japan mutual recognition agreement (MRA), which was first signed in 2004, has been expanded to include drug substances (active ingredients), sterile drugs and biological drugs such as vaccines as a result of the signing of the new comprehensive trade deal between the EU and Japan on 17 July 2018.

July 17, 2018, contributed by Ulrich BEHRENDT, Munich